Suppr超能文献

PRKAR1A 失活型黑色素瘤的基因组和临床病理特征:朝向动物型黑色素瘤/色素合成黑色素瘤的遗传特征区分。

Genomic and Clinicopathologic Characteristics of PRKAR1A-inactivated Melanomas: Toward Genetic Distinctions of Animal-type Melanoma/Pigment Synthesizing Melanoma.

机构信息

Departments of Pathology.

Dermatology, University of California, San Francisco.

出版信息

Am J Surg Pathol. 2020 Jun;44(6):805-816. doi: 10.1097/PAS.0000000000001458.

Abstract

Melanocytic tumors with inactivation of protein kinase A regulatory subunit-α (PRKAR1A) have large oval nuclei and intense pigmentation. Historically, these tumors have been categorized under various names, including epithelioid blue nevus, pigmented epithelioid melanocytoma (PEM) and animal-type melanoma. Although a subset of PEM harbor BRAF activating mutations and biallelic inactivation of PRKAR1A, there are only a few reports of melanomas, or of tumors with genomic alterations beyond those of PEMs. Herein, we describe the clinicopathologic and genetic features of 8 melanomas and tumors that lack PRKAR1α expression by immunohistochemistry but do not fit with conventional PRKAR1A-inactivated melanocytomas. These tumors tended to affect younger patients than conventional melanomas (median age=38 y) and presented as dark brown/black papules and nodules. Histopathologically, they demonstrated nodularity, sometimes in a background of conventional melanoma, and large vesicular nuclei with prominent nucleoli. With the exception of 1 case, the mitotic index was not significantly elevated. Immunohistochemically, all cases showed loss of PRKAR1α and of p16 expression. Seven tumors underwent massively parallel short read (next-generation) sequencing of a panel of 480 cancer-associated genes. Five tumors demonstrated truncating mutations of PRKAR1A and the 2 in which such mutations were not identified demonstrated loss of heterozygosity of the PRKAR1A locus. Four of the tumors harbored BRAF V600E mutations, and 1 harbored a FAM39B-BRAF gene fusion. Another harbored a GNA11 activating mutation. A MAP kinase activating mutation was not identified in the remaining case. Four tumors displayed TERT promoter mutations and chromosomal copy number changes supporting the diagnosis of melanoma. Two cases without these alterations and were classified as "high-grade PRKAR1A-inactivated melanocytomas". The 1 case with widespread metastases demonstrated mutations in TP53 and RB1. Overall, we provide the first genetic characterization of PRKAR1A-inactivated melanomas, discuss the differential diagnosis of heavily pigmented epithelioid melanocytic neoplasms, and propose a new nomenclature for such tumors.

摘要

具有蛋白激酶 A 调节亚基-α(PRKAR1A)失活的黑色素细胞肿瘤具有大的卵圆形核和强烈的色素沉着。历史上,这些肿瘤被归类为各种名称,包括上皮样蓝痣、色素性上皮样黑色素细胞瘤(PEM)和动物型黑色素瘤。尽管 PEM 的亚组存在 BRAF 激活突变和 PRKAR1A 的双等位基因失活,但仅有少数关于黑色素瘤或除 PEM 以外具有基因组改变的肿瘤的报道。在此,我们描述了 8 例黑色素瘤和肿瘤的临床病理和遗传特征,这些肿瘤通过免疫组织化学缺乏 PRKAR1α 表达,但不符合常规 PRKAR1A 失活的黑色素细胞瘤。这些肿瘤倾向于影响比传统黑色素瘤更年轻的患者(中位年龄=38 岁),表现为深棕色/黑色丘疹和结节。组织病理学上,它们表现为结节性,有时在常规黑色素瘤的背景下,并且具有大泡状核和明显的核仁。除 1 例外,有丝分裂指数均未显著升高。免疫组织化学上,所有病例均显示 PRKAR1α 和 p16 表达缺失。7 例肿瘤进行了 480 个癌症相关基因的大量平行短读(下一代)测序。5 例肿瘤显示 PRKAR1A 的截断突变,而在未发现此类突变的 2 例中,PRKAR1A 基因座显示杂合性丢失。4 例肿瘤携带 BRAF V600E 突变,1 例携带 FAM39B-BRAF 基因融合。另 1 例携带 GNA11 激活突变。在剩余的病例中未发现 MAP 激酶激活突变。4 例肿瘤显示 TERT 启动子突变和染色体拷贝数改变,支持黑色素瘤的诊断。2 例无这些改变的病例被归类为“高级别 PRKAR1A 失活的黑色素细胞瘤”。1 例广泛转移的病例显示 TP53 和 RB1 突变。总的来说,我们提供了 PRKAR1A 失活黑色素瘤的首次遗传特征描述,讨论了重度色素上皮样黑色素细胞肿瘤的鉴别诊断,并为此类肿瘤提出了新的命名法。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验